GlassScriptPhysician profile
Mary Hunt
NPI 1497799563
$2,041.49
in general payments reported to CMS, 2019-2025
23 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $45.73 · 2021: $450 · 2023: $267 · 2024: $119 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,236.50 | 2019-2021 | |
| Astellas Pharma US INC | $151.00 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $78.19 | 2023 | |
| Abbvie INC. | $59.68 | 2019-2023 | |
| Pfizer INC. | $51.69 | 2023 | |
| Sage Therapeutics, LLC | $50.65 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $46.23 | 2023-2025 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Vertical Pharmaceuticals, LLC | $41.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.70 | 2020-2023 | |
| Gilead Sciences, INC. | $33.96 | 2025 | |
| Organon LLC | $33.34 | 2024-2025 | Jada System |
| Merck Sharp & Dohme LLC | $31.95 | 2019-2023 | Gardasil 9 |
| Amag Pharmaceuticals, INC. | $27.70 | 2019 | |
| Hologic Sales and Service, LLC | $25.16 | 2024 | Aptima |
| Mimedx Group, INC. | $20.82 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $18.64 | 2025 | Livmarli |
| Solventum Corporation | $18.56 | 2025 | V.A.C.Ulta, Prevena |
| Millicent US INC | $17.76 | 2025 | Femlyv |
| Allergan, INC. | $17.00 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $16.60 | 2023 | Vivjoa |
| Therapeuticsmd, INC. | $15.00 | 2019 | |
| Exeltis, USA INC. | $14.91 | 2025 | Slynd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.